The trillion-dollar club has become crowded with mostly tech names riding the AI boom. Eli Lilly might soon join them for a ...

GLP-1 RAs, particularly semaglutide and tirzepatide, outperform older medications in achieving significant weight loss in adults with and without type 2 diabetes. Semaglutide and tirzepatide met ...

The new generation of obesity medications are inducing greater weight loss than any prior pharmacotherapy. There is discussion now about how to support fat loss while protecting lean mass.“Lean mass ...

Researchers reported that Eli Lilly’s GLP-1 weight-loss drug appeared to temporarily suppress food-craving signals in the ...

Lilly shines for growth seekers while J&J offers steady, lower-risk stability as both pharma giants advance pipelines and ...

Aspen Pharmacare Holdings Limited reported a significant financial performance for the first half of 2024, with the company surpassing its financial guidance amid strategic acquisitions and enhanced ...

By moving early, Novo Nordisk has got in with its price cut ahead of Lilly, whose deal involved dual GLP-1/CIP agonist ...

Eli Lilly and Company (NYSE:LLY) is one of the 15 Best Aggressive Growth Stocks to Buy Right Now. On November 7, TD Cowen ...

Celebrity endorsements by Elon Musk and Serena Williams have pushed weight loss medication into the mainstream. Demand is so ...

Research reveals Eli Lilly's GLP-1 drug, tirzepatide, temporarily suppresses food cravings in a patient's brain reward center. While initial effects were promising, the impact faded over time. Results ...

The drugmaker said Monday that it has started selling higher doses of the injectable obesity treatment for $349 a month to ...

Researchers monitoring the brain activity of a patient with a severe binge-eating problem reported that Eli Lilly's GLP-1 ...